Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 84.45% is 55% above its 5-year average of 54.36%, near the high end of its 5-year range (42.70%–94.91%).
6.21% above its 12-month average of 79.51%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 79.92%.
GROSS MARGIN
84.45%
GROSS MARGIN AVG TTM
79.51%
GROSS MARGIN AVG 3Y
62.01%
GROSS MARGIN AVG 5Y
54.36%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.21%
CURRENT VS 3Y AVG
+36.19%
CURRENT VS 5Y AVG
+55.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 612 covered companies
CURRENT VS SECTOR MEDIAN
+96.81%
vs the sector median at left
Market Cap
$10.98M
Gross Margin
89.58%
TTM Avg
88.41%
3Y Avg
-34.57%
5Y Avg
-154.89%
Market Cap
$11.30M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
-4489.78%
Market Cap
$10.77M
Gross Margin
N/A
TTM Avg
-101.19%
3Y Avg
-33.23%
5Y Avg
-22.16%
Market Cap
$11.38M
Gross Margin
14.12%
TTM Avg
57.06%
3Y Avg
28.53%
5Y Avg
19.02%
Market Cap
$11.21M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$10.52M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$11.31M
Gross Margin
18.76%
TTM Avg
9.38%
3Y Avg
50.69%
5Y Avg
33.79%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biofrontera Inc. (BFRI) | $11.20M | 84.45% | 79.51% | 62.01% | 54.36% |
| BioVie Inc. (BIVI)vs › | $11.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cerenome, Inc. (CNSY)vs › | $10.98M | 89.58% | 88.41% | -34.57% | -154.89% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | 0.00% | 50.00% | 25.00% | -4489.78% |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.77M | N/A | -101.19% | -33.23% | -22.16% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.38M | 14.12% | 57.06% | 28.53% | 19.02% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| Satellos Bioscience Inc. (MSLE)vs › | $10.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.31M | 18.76% | 9.38% | 50.69% | 33.79% |
| Lantern Pharma Inc. (LTRN)vs › | $11.81M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
84.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 79.92% |
| 2026-03-31 | 81.84% |
| 2025-12-31 | 94.91% |
| 2025-09-30 | 70.44% |
| 2025-06-30 | 70.45% |
| 2025-03-31 | 61.61% |
| 2024-12-31 | 58.02% |
| 2024-09-30 | 45.88% |
| 2024-06-30 | 44.61% |
| 2024-03-31 | 50.06% |
| 2023-12-31 | 49.34% |
| 2023-09-30 | 48.40% |
| 2023-06-30 | 50.62% |
| 2023-03-31 | 47.35% |
| 2022-12-31 | 48.19% |
| 2022-09-30 | 48.52% |
| 2022-06-30 | 42.70% |
| 2022-03-31 | 47.18% |
| 2021-12-31 | 47.94% |
| 2021-09-30 | 47.16% |
| 2021-06-30 | 46.92% |
| 2021-03-31 | 45.81% |
| 2020-12-31 | 48.39% |
| 2020-09-30 | 68.85% |
| 2020-06-30 | 42.42% |
| 2020-03-31 | 45.32% |
